Skip to main content
Onesource Specialty Pharma Limited logo

Onesource Specialty Pharma Limited — Investor Relations & Filings

Ticker · ONESOURCE ISIN · INE013P01021 LEI · 335800TP5C932B9IQT98 BSE.NS Manufacturing
Open in API
Filings indexed 156 across all filing types
Latest filing 2025-07-31 Declaration of Voting R…
Country IN India
Listing BSE.NS ONESOURCE

About Onesource Specialty Pharma Limited

https://www.onesourcecdmo.com/

Onesource Specialty Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) providing integrated solutions for complex pharmaceutical products. The company focuses on the development and large-scale manufacturing of specialty injectables, softgel capsules, and complex formulations. Its service portfolio encompasses the entire product lifecycle, including formulation development, clinical trial supply, and commercial-stage production. Onesource operates advanced manufacturing facilities designed to meet global regulatory standards, catering to diverse therapeutic areas. By leveraging technical expertise in sterile products and differentiated dosage forms, the organization supports global pharmaceutical partners in bringing high-entry-barrier medicines to market. The platform is built on a foundation of quality compliance and operational excellence to ensure the delivery of critical healthcare solutions.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding the voting results of a Postal Ballot conducted by OneSource Specialty Pharma Limited. It references Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of voting results. The document includes detailed voting results, the Scrutinizer's report, and confirms that resolutions were passed. It is not a full annual report, earnings release, or management discussion but specifically the official announcement of voting results from a shareholder meeting conducted via postal ballot and e-voting. The presence of detailed voting data and the Scrutinizer's report confirms this is a Declaration of Voting Results document. The document length (15,000 characters) and content confirm it is not a mere announcement of a report but the actual voting results filing. Therefore, the correct classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-07-31 English
Analysts/Institutional Investor Meet/Con. Call Updates
Capital/Financing Update Classification · 85% confidence The document is an intimation under SEBI Listing Regulations about an upcoming Board meeting to approve unaudited financial results for the quarter ended June 30, 2025. It also announces an earnings call scheduled for August 5, 2025, to discuss these financial results. The document does not contain the financial results themselves but is a notice about the meeting and the earnings call. The length is about 3050 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as a Capital/Financing Update (CAP) because it relates to financial results announcement scheduling and investor engagement activities, or possibly as a Regulatory Filing (RNS) since it is an official regulatory intimation. However, since it specifically announces the earnings call and the board meeting for financial results approval, the best fit is Capital/Financing Update (CAP).
2025-07-31 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about a scheduled Board Meeting to consider and approve the un-audited financial results for the quarter ended June 30, 2025. It references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about Board Meetings. The document does not contain the financial results themselves but is an announcement of the upcoming Board Meeting where such results will be approved. The document length is short (1952 characters) and it serves as an intimation rather than a report. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit into other specific categories like Interim Report or Earnings Release, which would require actual financial data or results.
2025-07-29 English
Board Meeting — OneSource Specialty Pharma Limited has informed the Exchange about Board Meeting to be held on 04-Aug-2025 to inter-alia consider and approve the Unaudited Financial results of the Co…
Regulatory Filings
2025-07-29 English
Updates
Regulatory Filings
2025-07-14 English
Reply to Clarification- Financial results
Regulatory Filings
2025-07-08 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.